Inovio Pharmaceuticals, Inc. (INO)

9,68 -0,52 (-5,10%) Börsenschluss: 04:00PM EDT

Inovio Pharmaceuticals, Inc.

660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462
United States
267 440 4200
https://www.inovio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 122

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jacqueline E. Shea Ph.D.	CEO, President & Director	1,13M	N/A	1966
Mr. Peter D. Kies	Chief Financial Officer	810,2k	N/A	1963
Dr. Laurent M. Humeau Ph.D.	Chief Scientific Officer	794,08k	N/A	1967
Thomas Hong	Manager of Investor Relations	N/A	N/A	N/A
Mr. Robert L. Crotty J.D.	General Counsel & Chief Compliance Officer	N/A	N/A	1974
Mr. E. J. Brandreth MBA	Senior Vice President of Quality Assurance	N/A	N/A	N/A
Dr. Jeffrey Skolnik	Senior Vice President of Clinical Development	N/A	N/A	N/A
Mr. Robert J. Juba Jr.	Senior Vice President of Biological Manufacturing & Clinical Supply Management	N/A	N/A	N/A
Mr. Stephen Kemmerrer M.B.A., P.E.	Senior Vice President of Engineering Development	N/A	N/A	N/A
Mr. Shawn D. Bridy M.A., M.B.A.	Senior Vice President of Business Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Corporate Governance

Inovio Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 7. Die grundlegenden Scores sind Audit: 8, Vorstand: 3, Shareholderrechte: 4, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.